Becton Dickinson & Co (BDX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com11-08

Q4 Revenue Growth: 7.4% overall growth, 6.2% organic growth. Full Year Organic Revenue Growth: 5%. Adjusted Diluted EPS: $13.14, up 11.4% for Q4 and 7.6% for the full year. Adjusted Operating Margin: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481148953?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.pU6Gwnh5bp.YzHPa0ynzQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/375a2ba00aa4d98459846d1f6c1cf5fd","is_english":true,"pubTime":"2024-11-08 15:07","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481148953","market":"us","top_or_hot":-1,"title":"Becton Dickinson & Co (BDX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...","media":"GuruFocus.com","content":"<div>\n<p>Q4 Revenue Growth: 7.4% overall growth, 6.2% organic growth.\nFull Year Organic Revenue Growth: 5%.\nAdjusted Diluted EPS: $13.14, up 11.4% for Q4 and 7.6% for the full year.\nAdjusted Operating Margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/becton-dickinson-co-bdx-q4-070710763.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Becton Dickinson & Co (BDX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBecton Dickinson & Co (BDX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 15:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/becton-dickinson-co-bdx-q4-070710763.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Q4 Revenue Growth: 7.4% overall growth, 6.2% organic growth.\nFull Year Organic Revenue Growth: 5%.\nAdjusted Diluted EPS: $13.14, up 11.4% for Q4 and 7.6% for the full year.\nAdjusted Operating Margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/becton-dickinson-co-bdx-q4-070710763.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDX","symbol_name":"碧迪医疗","start_time":0,"source_url":"https://finance.yahoo.com/news/becton-dickinson-co-bdx-q4-070710763.html","article_id":"2481148953","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.pU6Gwnh5bp.YzHPa0ynzQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/375a2ba00aa4d98459846d1f6c1cf5fd"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481148953","pubTimestamp":1731049630,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Q4 Revenue Growth: 7.4% overall growth, 6.2% organic growth.Adjusted Diluted EPS: $13.14, up 11.4% for Q4 and 7.6% for the full year.Adjusted Operating Margin: 24.2% for the full year, 26.6% for Q4.Free Cash Flow: $3.1 billion, a 47% increase.BD Medical Segment Growth: Driven by infusion systems and prefilled devices for biologic drugs.BD Life Sciences Growth: Led by specimen management and molecular platform growth.BD Interventional Growth: Double-digit growth in PureWick franchise and advanced repair and reconstruction.Net Leverage: 3 times, with a target to reduce to 2.5 times in 12-18 months.Fiscal Year 2025 Revenue Guidance: $21.9 billion to $22.1 billion, with 8.8% to 9.3% currency-neutral growth.GuruFocus has detected 5 Warning Sign with BDX.Becton Dickinson & Co  reported strong Q4 results with 7.4% revenue growth and 11.4% increase in adjusted diluted EPS.BDX's med tech and diagnostics businesses grew by 5.9%, demonstrating resilience despite challenges in China.BDX announced ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BDX":"碧迪医疗"},"translate_title":"Becton Dickinson&Co(BDX)2024年第四季度收益看涨期权亮点：强劲的收入增长和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1},"content_text":"Q4 Revenue Growth: 7.4% overall growth, 6.2% organic growth.\nFull Year Organic Revenue Growth: 5%.\nAdjusted Diluted EPS: $13.14, up 11.4% for Q4 and 7.6% for the full year.\nAdjusted Operating Margin: 24.2% for the full year, 26.6% for Q4.\nFree Cash Flow: $3.1 billion, a 47% increase.\nBD Medical Segment Growth: Driven by infusion systems and prefilled devices for biologic drugs.\nBD Life Sciences Growth: Led by specimen management and molecular platform growth.\nBD Interventional Growth: Double-digit growth in PureWick franchise and advanced repair and reconstruction.\nNet Leverage: 3 times, with a target to reduce to 2.5 times in 12-18 months.\nFiscal Year 2025 Revenue Guidance: $21.9 billion to $22.1 billion, with 8.8% to 9.3% currency-neutral growth.\nFiscal Year 2025 Adjusted EPS Guidance: $14.25 to $14.60.\n\n\nWarning! GuruFocus has detected 5 Warning Sign with BDX.\n\nRelease Date: November 07, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nBecton Dickinson & Co (NYSE:BDX) reported strong Q4 results with 7.4% revenue growth and 11.4% increase in adjusted diluted EPS.\nThe company achieved 120 basis points of margin expansion and delivered a full-year EPS of $13.14, exceeding initial expectations.\nBDX's med tech and diagnostics businesses grew by 5.9%, demonstrating resilience despite challenges in China.\nThe company successfully integrated Advanced Patient Monitoring, contributing $74 million to BD Medical revenue.\nBDX announced its 53rd consecutive year of dividend increases, highlighting its commitment to returning capital to shareholders.\n\n Negative Points \n\nFiscal 2024 revenue growth was below initial expectations due to complex market dynamics in China and bioscience pharma.\nThe bioscience pharma segment only grew by about 1%, reflecting challenges in market demand.\nBDX anticipates a mid-single-digit decline in China revenues for FY25 due to value-based procurement dynamics.\nThe company expects a moderate step back in free cash flow conversion to around 75% due to integration-related investments for APM.\nHigher interest expenses and a higher tax rate, including the impact of Pillar 2, are expected to affect FY25 financials.\n\n Q & A Highlights \nQ: Can you provide more details on the guidance for fiscal 2025, particularly regarding the 125 basis points headwinds on pharma biosciences in China? A: Thomas Polen, Chairman, CEO, and President, explained that the guidance assumes a cautious view on China with a mid-single-digit decline due to value-based procurement dynamics. The bioscience pharma space is expected to continue at a similar rate to 2024, given the uncertainty in recovery timing. Despite these headwinds, BD remains confident in its long-term strategic position and competitive execution in these markets.\nQ: Did Alaris meet its fiscal 2024 goal, and what are the expectations for fiscal 2025? A: Thomas Polen confirmed that Alaris exceeded the $350 million goal for fiscal 2024. Michael Garrison, President of the Medical Segment, added that Alaris performed well in the quarter, and BD is optimistic about its continued strong growth into fiscal 2025, with a focus on rebuilding committed contract backlogs.\nQ: How is BD addressing potential tariffs and supply chain impacts, and what is the strategy regarding pricing? A: Thomas Polen stated that BD's strategy involves strong local manufacturing in China for China, minimizing export impacts. BD is well-positioned with a network designed to serve local markets, which helps mitigate tariff impacts. The company will continue to monitor the situation closely.\nQ: Could you elaborate on BD's AI strategy and its integration into products? A: Thomas Polen highlighted BD's ongoing AI initiatives, including existing products with AI capabilities like microbiology automation and narcotic diversion detection. BD is investing in AI to enhance patient care and operational efficiency, with plans to integrate AI into new platforms, starting with the Pyxis platform. More details will be shared at the upcoming Investor Day.\nQ: What are BD's capital allocation priorities following the $1 billion share repurchase announcement? A: Christopher DelOrefice, CFO, emphasized that BD's capital allocation priorities remain unchanged, focusing on dividends, tuck-in M&A, and deleveraging. The strong cash flow position allows for increased share repurchases while maintaining the commitment to reduce net leverage to 2.5 times within 12 to 18 months.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481148953"}